Allergic diseases are driven by activation of mast cells and release of mediators in response to IgE-directed antigens. However, there are no drugs currently available that can specifically down-regulate mast cell function in vivo when chronically administered. Here, we describe an innovative approach for targeting mast cells in vitro and in vivo using antisense oligonucleotide-mediated exon skipping of the β-subunit of the high-affinity IgE receptor (FceRIβ) to eliminate surface high-affinity IgE receptor (FceRI) expression and function, rendering mast cells unresponsive to IgE-mediated activation. As FceRIβ expression is restricted to mast cells and basophils, this approach would selectively target these cell types. Given the success of exon skipping in clinical trials to treat genetic diseases such as Duchenne muscular dystrophy, we propose that exon skipping of FceRIβ is a potential approach for mast cell-specific treatment of allergic diseases. mast cell | allergy | IgE receptor | oligonucleotides | dermatitis A sthma and related allergic diseases affect up to 1 in 10 people in developed countries, and about 10% of patients with asthma cannot be controlled with current therapeutic approaches. The most widely used therapies for asthma rely upon dampening the inflammatory response with either oral or inhaled glucocorticosteroids and relaxing the constricted airway smooth muscle cells with β-adrenoreceptor agonists. However, high doses of steroids when needed for severe asthma are associated with undesirable side effects and inhaled β-adrenoreceptor agonists can increase the risk of death from asthma if not used in combination with glucocorticosteroids. It is suggested that β-adrenoreceptor agonists may promote underlying inflammation that could contribute to the airway wall remodeling seen in asthma (1). Other clinical approaches that aim for more long-term alleviation of symptoms, including desensitization with incremental increases in dose of allergen or hyposensitization to induce immune tolerance, have proven beneficial for some, but not all, patients, and serious adverse effects can occur (2).
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mast cell | allergy | IgE receptor | oligonucleotides | dermatitis A sthma and related allergic diseases affect up to 1 in 10 people in developed countries, and about 10% of patients with asthma cannot be controlled with current therapeutic approaches. The most widely used therapies for asthma rely upon dampening the inflammatory response with either oral or inhaled glucocorticosteroids and relaxing the constricted airway smooth muscle cells with β-adrenoreceptor agonists. However, high doses of steroids when needed for severe asthma are associated with undesirable side effects and inhaled β-adrenoreceptor agonists can increase the risk of death from asthma if not used in combination with glucocorticosteroids. It is suggested that β-adrenoreceptor agonists may promote underlying inflammation that could contribute to the airway wall remodeling seen in asthma (1) . Other clinical approaches that aim for more long-term alleviation of symptoms, including desensitization with incremental increases in dose of allergen or hyposensitization to induce immune tolerance, have proven beneficial for some, but not all, patients, and serious adverse effects can occur (2) .
In addition to asthma, other allergic diseases have similar treatment strategies and also have an unmet clinical need. An example is atopic dermatitis (AD), which like asthma, is also a multifactorial disease with complex pathophysiology, remains incurable, and affects 10-20% of children in the United States (3). The two major symptoms of AD are inflammatory lesions and severe pruritus. Both the prevalence and the economic burden of AD are increasing worldwide. Symptomatic treatment with topical and/or systemic glucocorticosteroids or calcineurin inhibitors are still considered the gold standard. However, due to the known adverse effects of these drugs, prescription rates are low and patient compliance is often poor (3). Thus, there is still a need for new therapeutic approaches with a better safety profile.
An approach for intervention in allergic inflammation that we have pursued is based on the finding that the gene loci 11q12-q13 are strongly linked to allergy and asthma susceptibility and that the membrane spanning 4A (MS4A) gene family is clustered around 11q12-q13 (4-7). Moreover, the genes MS4A1 (encoding the protein CD20) and MS4A2 [encoding the protein FceRIβ (β-subunit of the high-affinity IgE receptor)] are associated with the activation and proliferation of B cells (8) and mast cells (9) (10) (11) , respectively, and are therefore considered potential candidates for the linkage of these genetic regions with allergy. In particular, FceRIβ contributes to IgEdependent mast cell signaling by trafficking the FceRI receptor complex to the cell surface and amplifying FceRI-induced signaling (12, 13) . The first transmembrane domain of FceRIβ is required for trafficking the receptor complex (14) , whereas the C-terminal immunoreceptor tyrosine-based activation motif (ITAM) amplifies signaling (15) . Thus, a report that polymorphisms in MS4A2 were associated with development of asthma gained interest (16) , but studies into the functional consequence of mutations in MS4A2 did not appear to affect the function of FceRIβ (17) . However, we have identified the expression of a truncated isoform of FceRIβ (t-FceRIβ) that lacks exon 3 of MS4A2, which encodes the first two transmembrane domains of FceRIβ (10) . This truncated isoform does not traffic to the plasma membrane (9, 10) and appears to function in intracellular rather than plasma transmembrane signaling (9) . Therefore, our hypothesis is that perturbation of MS4A2 splicing could lead to disproportionate expression of the t-FceRIβ isoform at the expense of full-length (FL) FceRIβ isoform and thus perturb trafficking of the FceRI receptor complex to the plasma membrane as well as mast cell responses to IgE-directed antigens.
Here, we have examined whether manipulation of MS4A2 splicing favors t-FceRIβ formation, disrupts FceRI expression and signaling, and has functional consequences. We identified that forced expression of t-FceRIβ using antisense oligonucleotide (AON)-mediated exon skipping of MS4A2 exon 3 eliminated expression of FceRI in
Significance
We identified an innovative use for the technique of antisense oligonucleotide-mediated exon skipping to specifically target and down-regulate IgE receptor expression in mast cells. Exon skipping is typically used as part of personalized medicine, where a mutant exon is skipped after sequencing the patients' affected genes. Our approach, however, targets a nonmutated gene and an exon that is critical for surface IgE receptor expression. It does not require a personalized approach with genetic sequencing or multiple iterations of oligonucleotides that would require clinical trials. Furthermore, the diseases to be treated with this technology are ideal for local delivery of the oligonucleotides by aerosols or topical cream formulations. mast cells and resulted in mast cells that were functionally unresponsive to IgE-mediated antigen challenge. Given the recent promising results of using AONs to alter splicing in diseases (for reviews, see refs. [18] [19] [20] , and their success in clinical trials for Duchenne muscular dystrophy (21, 22) , we propose that our results warrant further study to develop this approach as a potential mast cell-specific treatment for allergic diseases.
Results
Loss of FceRI with FceRIβ Exon Skipping. We first tested whether AONs could be efficiently transfected into mast cells using a control 25-mer FITC-conjugated morpholino AON in primary mouse bone marrow-derived mast cells (BMMCs). We achieved >95% efficiency in mouse BMMCs at 24 h ( Fig. 1 A and B) with no evidence of cytotoxicity as determined by propidium iodide staining (Fig. 1A) .
The naturally occurring truncation of MS4A2 exon 3 leads to loss of the first two transmembrane domains of FceRIβ resulting in the expression of t-FceRIβ that does not traffic to the plasma membrane nor associate with FceRI (9, 10) . Therefore, we predicted that skipping exon 3 of MS4A2 following FceRIβ AON treatment would result in preferential production of t-FceRIβ instead of FL FceRIβ as well as loss of expression of surface FceRI, which is dependent on FL FceRIβ (9, (12) (13) (14) . We attempted to induce exon skipping with AONs designed to target Ms4a2 exon 3 at the intron-exon boundary and identified that FceRIβ AONs dose-dependently induced exon skipping of FceRIβ mRNA as indicated by RT-PCR compared with cells transfected with an equivalent 25-mer standard control AON (Fig. 1C) .
To test whether exon skipping leads to loss of surface expression of FceRI, we used flow cytometry to measure surface FceRI expression in mouse BMMCs and found that it was reduced after 10 μM FceRIβ AON treatment by 95.6 ± 0.4% (n = 5; P < 0.001) (Fig. 1D ), thus virtually eliminating FceRI expression (efficiency of transfection was ∼95%). In agreement with the exon-skipping data (Fig. 1C) , the effects of FceRIβ AONs on surface FceRI expression were also dose dependent (Fig. 1E ).
Degranulation and Calcium Influx. In view of the loss of surface FceRI expression with FceRIβ AON transfection, we tested whether there were corresponding reductions in responses to antigen in BMMCs. There was a dose-dependent decrease in degranulation in response to DNP with increasing concentrations of FceRIβ AON, and degranulation was eliminated with 10 μM FceRIβ AON ( Fig.  2A) . One micromolar FceRIβ AON resulted in 80% reduction in surface FceRI expression (Fig. 1C) whereas the reduction in degranulation was lower (∼25%), although significant ( Fig. 2A) . A possible explanation for this finding is that the number of FceRI receptors and signaling capacity appears to exceed the requirements for degranulation, an explanation in agreement with studies reported in RBL-2H3 mast cells (23) . Although FceRI numbers vary during the cell cycle (24) and among different mast cell types, with estimates from 130,000 in human lung mast cells (25) to ∼290,000 per cell in RBL-2H3 cells (23) and 120,000-380,000 in human cord bloodderived mast cell/basophil cultures (26) , it is likely that mast cells in general harbor surplus FceRI as significant degranulation is observed with aggregation of a few hundred receptors (23) .
The specificity of FceRIβ AON treatment was next determined by its effect on thapsigargin-induced degranulation. Although FceRIdependent degranulation was eliminated in BMMCs, thapsigargininduced degranulation was unaffected by FceRIβ exon skipping (Fig.  2B ). In addition, we found the same pattern for calcium mobilization with robust inhibition of the calcium signal in response to FceRI aggregation whereas the response to thapsigargin was unaffected (Fig. 2C) . As with thapsigargin, IgE-mediated calcium influx is dependent upon store-operated calcium entry (27) . Therefore, FceRIβ exon skipping appears to selectively target IgE-dependent activation without disrupting cell responses to other stimuli.
Signaling, Cytokine Release, and Migration. We next examined the effects of FceRIβ exon skipping in BMMCs on cell signaling events that regulate both degranulation and de novo cytokine synthesis and in particular whether residual weak signals that fail to stimulate degranulation were still sufficient to induce synthesis of cytokines. As expected from the diminished calcium signal, we found no significant FceRI-mediated phosphorylation of PLCγ1 with FceRIβ AON transfection, and unlike FceRI-mediated activation, thapsigargin does not induce phosphorylation and acts independently of PLCγ ( Fig. 3 A and B) . Phosphorylation of AKT and ERK are more distal signals than PLCγ1 phosphorylation, but phosphorylation of both of AKT and ERK were also markedly reduced by FceRIβ exon skipping (Fig. 3 A, C, and D) . In contrast to PLCγ1, the AKT and ERK pathways are activated by thapsigargin, but neither AKT nor ERK phosphorylation was affected by FceRIβ exon skipping (Fig. 3 A, C, and D) .
Low-level activation of mast cells can result in the production of cytokines without evidence of acute signaling events. One such example is IgE alone, which did not elicit rapid phosphorylation of PLCγ1, AKT, or ERK (Fig. 3 A-D) , but did cause release of the cytokine GM-CSF after 6 h (Fig. 3E) . Nevertheless, this release, as well as that induced by IgE plus antigen to induce FceRI aggregation, was blocked by FceRIβ exon skipping without affecting thapsigargin-induced GM-CSF release in BMMCs (Fig. 3E) .
We also examined the effects of exon skipping on antigenmediated BMMC migration (28) . Standard control AON-treated BMMCs that were sensitized with IgE migrated toward antigen (DNP-BSA), but FceRIβ AON-treated BMMCs did not (Fig.  3F) . However, BMMC migration mediated through KIT, the receptor for stem cell factor (SCF) was not reduced and if anything it was enhanced by FceRIβ exon skipping, although not to a statistically significant extent (Fig. 3F) 
Survival and Proliferation. In addition to the classical view that IgE binding to FceRI on mast cells primes mast cells for activation by bivalent/multivalent antigens, it is now recognized that IgE binding to FceRI leads to activation of mast cells to release prosurvival cytokines that maintain viability of the cells (29) (30) (31) . In the absence of external supporting cytokines, mast cells rapidly undergo apoptosis, which is suppressed by the addition of IgE. Therefore, elevation of tissue IgE during allergic diseases, such as the lung in asthma or the skin in AD, could contribute to increased mast cell numbers by promoting cytokine release and mast cell survival. We therefore tested whether FceRIβ exon skipping would also eliminate the prosurvival effect of IgE on mast cells. BMMCs were deprived of the culture growth-promoting cytokine, IL-3, for 24 h after transfection with AONs. Over the course of 72 h, IgE almost completely protected mast cells from cell death and apoptosis after withdrawal of IL-3 in control AON-treated BMMCs (Fig.  S1) . However, treatment of BMMCs with FceRIβ AON, which resulted in loss of surface FceRI expression (Fig. S1) , eliminated the protective effect of IgE after IL-3 withdrawal (Fig. S1) . The apparent decrease in FceRI expression in the presence of IgE we believe reflects the decreased affinity of MAR-1 for FceRI once it is occupied by IgE (32) . Taken together, FceRIβ exon skipping could potentially suppress the prosurvival effect of elevated IgE in vivo and thus the increase in mast cell population as well as reduce IgE-dependent degranulation in allergic disease.
We next examined the effects of FceRIβ exon skipping (day 0) on mast cell proliferation in the presence of IL-3, while monitoring both surface FceRI expression (Fig. S2 ) and proliferation using a CellTrace Violet dilution assay (Fig. S2) . The majority of the proliferation occurred between day 5 and day 7 with a population of cells appearing with diluted CellTrace dye at day 7 (Fig. S2) . There was no difference in proliferation in the absence or presence of FceRIβ exon skipping at either 5 or 7 d. There was a population of BMMCs treated with FceRIβ AON that began to express FceRI on the surface at day 7, despite all of the cells at day 5 being negative for surface FceRI (Fig. S2) , suggesting that these cells were regaining FceRI expression. Gating the populations of cells based on surface FceRI expression and plotting CellTrace Violet fluorescence demonstrated that the cells expressing surface FceRI were the cells that had proliferated (Fig. S2) . These data most likely indicate that, although overall proliferation is not affected by FceRIβ AON treatment, BMMCs that do proliferate dilute the FceRIβ AON between daughter cells, thus reducing exon-skipping efficacy.
In Vivo Passive Cutaneous Anaphylaxis. As proof-of-concept of therapeutic utility, we sought evidence that the FceRIβ exon-skipping approach is effective in vivo, having in mind the possibility of delivering FceRIβ AONs locally to affected tissues in allergic diseases such as allergic rhinitis, asthma, or atopic dermatitis. Localized administration of FceRIβ AON would take advantage of its specificity toward FceRI-mediated responses and restrict targeting to mast cells in the affected tissue. Therefore, we used the well-established model of passive cutaneous anaphylaxis (PCA) to test the efficacy of localized delivery of the AONs by means of the Vivo-Morpholino AONs. With this approach, we observed a partial but substantial reduction in PCA reaction with administration of FceRIβ AON compared with control AON (Fig. 4A) . Examination of total RNA isolated from skin adjacent to the injected ears by qualitative RT-PCR revealed that the administration of FceRIβ AON had resulted in exon skipping in vivo (Fig. 4B) . The efficiency of exon skipping in vivo was less than that observed in BMMC cultures, which is consistent with the partial reduction in the PCA reaction compared with near-complete block of degranulation in BMMCs (Fig. 2) . We also note that, in this PCA model, as in cell culture, FceRI receptors are saturated with DNP-specific IgE, whereas in a naturally occurring allergic disease only a minor fraction of receptors may be occupied by an allergen-specific IgE and thus could be more susceptible to FceRIβ exon-skipping therapy.
In Vivo Allergic Dermatitis Model. As further evidence of therapeutic potential for FceRIβ AON administration, we used an established allergic dermatitis model using toluenediisocyanate (TDI) to sensitize the mice as described in Materials and Methods. FceRIβ AON or standard control AON were injected into the ears either after sensitization and before TDI challenge (Fig. S3) or with once-weekly injections for 4 wk during sensitization to demonstrate improvement over time (Fig. 5) . Using these models, we were able to assess both the immediate and late-phase allergic responses. Both the immediate response at 1 h postchallenge and the late-phase response at 24 h postchallenge were markedly reduced after weekly injections of FceRIβ AON compared with standard control AON (Fig. 5A) . At 24 h postchallenge, we performed histological analysis of the ears for inflammation by assessing cellular influx and edema in the H&E-stained skin sections and identified a significant reduction in inflammation with FceRIβ AON treatment (Fig. 5 B  and C) . We also measured inflammatory cytokines in the ear skin 24 h postchallenge and found markedly reduced levels with FceRIβ AON treatment compared with standard control AONtreated mice (Fig. 5 D-G) . Similar results were observed if FceRIβ AON treatment was administered after the mice were sensitized (Fig. S3) , although the efficacy was less than in mice receiving five injections. Taken together, these data indicate that FceRIβ AON treatment reduces both early and late-phase inflammatory responses in a TDI-induced allergic dermatitis model and that repeated administration of FceRIβ AONs could have prophylactic potential for treating allergic inflammation.
Proof-of-Principle in Human Mast Cells. To confirm that the findings in our mouse models translate to humans, we next tested whether exon skipping of FceRIβ resulted in reduced FceRI expression and IgE-dependent degranulation in human mast cells. The human MS4A2 gene contains AT-rich regions in the splicing donor or acceptor sites at the intron-exon or exon-intron boundaries of exon 3 reducing RNA binding affinity of AONs. Thus, for human mast cells, we could achieve exon skipping, but with less efficiency than with BMMCs. Transfection of LAD-2 cells with an FceRIβ AON resulted in around 75% exon skipping as demonstrated by reduction in FL FceRIβ mRNA assessed with quantitative RT-PCR (Fig. 6A ). This degree of exon skipping resulted in a significant reduction in surface FceRIα expression of ∼50% (Fig.  6B) . We next confirmed that the reduction in FceRI surface expression with FceRIβ AON transfection resulted in reduced IgEdependent degranulation by cross-linking biotinylated IgE with streptavidin and identified a significant reduction in IgE-dependent degranulation (Fig. 6C) without observing any change in thapsigargin-induced degranulation (Fig. 6D) . Taken together, these data demonstrate that FceRIβ AONs act comparably in human mast cells as they do in mouse mast cells, although further refinement and screening of human constructs is required to achieve optimal exon skipping in human mast cells.
Discussion
Current treatments for allergic diseases generally rely upon neutralizing the effects of inflammatory mediators or dampening of the inflammatory response with steroids. A more desirable approach would be to suppress release or production of inflammatory mediators by targeting the principal effector immune cells. Targeting mast cell FceRI signaling pathways has been suggested given the preeminent role played by this cell and receptor in allergic disease. However, the same kinases and signaling molecules are used by other receptors in various immune cells, and targeting these signaling molecules is unlikely to achieve the required specificity. Targeting FceRI directly by inhibiting binding of IgE to FceRI is problematic because crosslinking FceRI with anti-FceRI antibodies mimics activation by antigen-inducing anaphylactic degranulation. An approach with some clinical success is the use of omalizumab, a humanized anti-IgE antibody that binds to the Fc fragment of IgE, blocking its binding to FceRI (for review, see ref. 33 ). Because omalizumab binds to IgE directly, it does not activate mast cells or interact with FceRI. However, a potential limitation is that other cells, such as dendritic cells (33) (34) (35) , express a trimeric form of FceRI (lacking FceRIβ expression) that functions in antigen presentation where IgE binding to trimeric FceRI may have immunoregulatory functions to dampen allergic responses (34) (35) (36) .
For the purpose of achieving selective targeting of mast cells and avoiding the limitations of previous therapies, the FceRIβ subunit appeared to be one promising candidate. Tetrameric FceRI contains α and β subunits associated with dimeric γ subunits, whereas trimeric FceRI consists of just the α and dimeric γ subunits (12, 33, 37) . Importantly, expression of tetrameric FceRI is restricted to mast cells and basophils, whereas trimeric FceRI that lack FceRIβ are expressed on dendritic and other cell types (12, (33) (34) (35) . In addition to being exclusively located in mast cells and basophils, FceRIβ is critically required for trafficking of FceRI to the cell surface in mast cells (9) . Although FceRIβ has been considered as a mast cell-specific target in recent years (9, 10, 12, 38) , the problem was how to effectively target FceRIβ. Delivery of siRNA or shRNA to silence FceRIβ is not totally effective in mast cells even with use of lentiviral delivery techniques and results in 50-80% reduction of protein expression (9, 39). We therefore considered the innovative approach of forcing the cell to produce an alternative splice variant of FceRIβ (t-FceRIβ) that does not associate with FceRIα or FceRIγ. The current study indicates that this approach works efficiently by eliminating surface FceRI expression and function, rendering mast cells completely unresponsive to IgE. This has significant implications on not only immediate mast cell activation and the wheal and flare reaction, but also on cytokine release and the late-phase allergic response, which we demonstrate is also reduced in an allergic dermatitis in vivo model. In addition, because IgE and FceRI act as prosurvival and chemoattractant factors for mast cells (28, 40) , AONinduced exon skipping of FceRIβ might reduce mast cell numbers in affected tissues by reducing mast cell recruitment and survival, thus increasing the efficacy of the drug. We are currently examining this in chronic allergy models. Importantly, we demonstrate FceRIβ exon skipping in vivo as a proof-of-concept for further development of AON-mediated altered splicing of FceRIβ as a therapeutic approach for allergic diseases.
Our studies provide important proof-of-concept data for developing AON-induced exon skipping of FceRIβ as a therapeutic and/or preventative treatment for allergic diseases. Our in vitro and in vivo mouse studies demonstrate surprisingly potent efficacy in vitro with a "knockout" effect and a more variable, but still impressive effectiveness in vivo with some mice exhibiting no histological evidence of inflammation 24 h after TDI challenge in the allergic dermatitis model. Although we demonstrate that efficient exon skipping can be achieved in skin mast cells in vivo, a limitation is that effective delivery of AONs into mast cells in skin is limited by diffusion of drug within the skin and the surface area of skin that can be infiltrated by intradermal injection. Systemically administered AONs distribute poorly into the skin and topical administration would be more desirable delivery mechanism for skin disorders. The AON system that we describe here is probably best suited for topical application. To develop this approach further, we need to identify effective methods of delivery over larger surface areas of skin and into other tissues of interest such as the airways. An additional limitation is that the sequence of the human MS4A2 gene is less conducive to exon skipping than the mouse Ms4a2. Although the experimental dermatitis model illustrated the full potential of the AON approach in mice, it is apparent that more refined AON configurations might be needed to achieve this in humans.
Despite these challenges, we believe that this approach has the potential for clinical application. AON-mediated exon skipping is emerging as a promising gene therapy approach with the advantage that it does not alter the genome and is reversible with cessation. Exon skipping has been effectively used for rare genetic defects where frameshift mutations in genomic DNA lead to loss of protein function (for reviews, see refs. [18] [19] [20] . Indeed, two new drug applications for the AON drugs Drisapersen (BioMarin Pharmaceutical) and Eteplirsen (Sarepta Therapeutics) to treat Duchenne muscular dystrophy have been filed with the Food and Drug Administration. However, exon skipping is predominantly used for rare genetic disorders that require gene sequencing, a personalized gene therapy approach, and separate clinical trials and approvals for each exon targeting AON, causing a burden on development. We have devised an AON approach to alter splicing of FceRIβ with the potential of treating allergic conditions such as asthma and atopic dermatitis, which are amenable to inhaled or topical treatments, respectively, and not associated with a specific genetic defect, thus eliminating the need for a personalized approach. Our data indicate that this could be a viable approach for treatment of allergic diseases and a mast cell-specific therapeutic strategy that, we believe, has the potential to translate into the clinic.
Materials and Methods
For additional information on methods, see SI Materials and Methods.
Experiments on mice carried out at NIH were conducted under a protocol approved by the Animal Care and Use Committee at National Institute of Allergy and Infectious Diseases (NIAID), NIH. BMMCs were developed from bone marrow obtained from femurs of C57BL/6J mice (The Jackson Laboratory), as previously described (41) .
Transfection of Mast Cells with AONs. Transfection was achieved using the Nucleofector II and Cell Line Kit V (Lonza) as described (9) , and program X-001 was used. AONs were purchased from Gene-Tools LLC.
Allergic Dermatitis TDI Model. Female 6-wk-old BALB/cAnN were purchased from Charles River Laboratories. All aspects of the current study were conducted in accordance with the Animal Care and Use Program of the North Carolina State University (Institutional Animal Care and Use Committee Protocol No. 13-111-B).
